Friday, April 13, 2018
News Recap:
Canada:
Initiative aims to treat Hepatitis C in Alberta patients who also have HIV. A long-term effort to eliminate Hepatitis C as a public health threat is underway in Alberta, where a new program aims to provide medications to one particularly vulnerable group of patients. NOTE: In Alberta, coverage has been expanded as of April 1 to include all patients with hepatitis C. Previously, coverage was provided only to...
71 million people stand to benefit from reduced price treatment for virus which can lead to liver cirrhosis, cancer and death.
An affordable hepatitis C treatment has been shown to be safe and effective, with very high cure rates for patients including hard-to-treat cases, in interim clinical trial results that offer hope to the 71 million people living with the disease worldwide.
The treatment is expected to cost $300 for 12 weeks, or $3.50 per day, i...
AMSTERDAM, April 21, 2017 /PRNewswire/ -- Agreement seeks to improve health options for hepatitis C patients in low- and middle-income countries
The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidel
The latest battle over access to medicines is taking place in Ukraine, where Doctors Without Borders is urging Gilead Sciences to drop a court action that, if successful, would prevent a generic version of the Sovaldi hepatitis C treatment from remaining available.
In a Sept. 5 letter released publicly Tuesday, Gilead was asked to “reconsider its business strategy in high-burden, middle-income countries, especially Ukraine,” since its strategies “threaten